Alberto
Carmona Bayonas
Asociado Ciencias de la Salud
![Foto de Alberto](/img/uploaded/c9d7750ad373785985563925a999eee0.jpeg)
![Foto de Hospital General Universitario de Alicante](/img/noimage_org.png)
Hospital General Universitario de Alicante
Alicante, EspañaPublicaciones en colaboración con investigadores/as de Hospital General Universitario de Alicante (7)
2024
-
Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry
Gastric Cancer, Vol. 27, Núm. 1, pp. 131-145
-
Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry
Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1674-1686
2023
-
Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry
Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 4077-4089
-
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
Therapeutic Advances in Medical Oncology, Vol. 15
2022
-
A Delphi Study on the Management of Neuropathic Cancer Pain in Spain: The DOLNEO Study
Journal of Pain Research, Vol. 15, pp. 2181-2196
-
Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
ESMO Open, Vol. 7, Núm. 3
2020
-
Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry
PloS one, Vol. 15, Núm. 7, pp. e0235848